Printer Friendly

PARKE-DAVIS OFFERS SINGLE AGENT COMMITMENT PROGRAM FOR NEW HYPERTENSION THERAPY

 PARKE-DAVIS OFFERS SINGLE AGENT
 COMMITMENT PROGRAM FOR NEW HYPERTENSION THERAPY
 MORRIS PLAINS, N.J., Dec. 10 /PRNewswire/ -- Parke-Davis, a division of Warner-Lambert Company (NYSE: WLA), today unveiled the Accupril(R) (quinapril HC1 tablets) Single Agent Commitment(TM) to underscore the effectiveness of its new antihypertensive medication.
 The Accupril Single Agent Commitment program will provide a value- added service, reinforcing the patient benefits of a single-handed approach to blood pressure reduction. Specifically, the Accupril Single Agent Commitment promises that Parke-Davis will pay for a diuretic if the physician decides that a patient requires it in addition to Accupril at any time during Accupril therapy. The new treatment is also available at a single price, regardless of tablet strength.
 "The Single Agent Commitment reflects the full measure of our confidence in the use of Accupril as 'one agent, once a day for many patients,'" said Parke-Davis President Joseph E. Smith. "Reducing blood pressure with a single agent provides hypertensive patients with valuable benefits, including avoiding the cost of a second agent and encouraging patient compliance.
 There is no other antihypertensive therapy that is backed by the Single Agent Commitment program."
 Single-Agent Benefits
 A simplified medication regime has important benefits. Some 50 percent of patients who are diagnosed with hypertension go off therapy within one year, largely because compliance is hindered by multi-drug therapy and because dual medications can compound unpleasant side effects. Considering that high blood pressure is one of the major risk factors of cardiovascular disease -- the leading cause of death in the United States -- a single-agent approach to therapy and its potential to improve compliance take on special significance.
 Accupril provides a strong patient benefit because it is available for the same price regardless of tablet strength. While many of the other angiotensin converting enzyme (ACE) inhibitors available have a "price to titrate," the Accupril one-price policy allows physicians to increase dosage strength up to 40 mg a day to control high blood pressure without patients having to face increased costs.
 Accupril, approved on Nov. 19 by the FDA for marketing in the United States for the treatment of hypertension, is indicated as single-agent therapy. Like other ACE inhibitors, Accupril lowers blood pressure by blocking the formation of angiotensin II, a powerful constrictor of blood vessels. However, Accupril also offers a single-handed approach to blood pressure reduction. The effect of Accupril on hypertension appears to result primarily from the inhibition of plasma and tissue ACE activity. In animal studies, there was a strong link between tissue ACE inhibition and blood pressure reduction, although the clinical significance of this inhibition has not been established in humans.
 ACE inhibitors are one of the fastest-growing segments among antihypertensive treatment, with U.S. sales exceeding $1.5 billion in 1991. They have no clinically significant adverse effects on cholesterol, insulin or glucose tolerance.
 Accupril is an excellent agent for the reduction of high blood pressure because of the low incidence of side effects associated with its use and because it offers for many patients single-agent therapy and once-daily dosing.
 High Standards for Hypertension Care
 According to the "1988 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure" (JNC IV) -- the bench mark of hypertension treatment issued by a panel of leading experts under the auspices of the National Heart, Lung and Blood Institute -- hypertension treatment goals should include tailored patient care, simplified medication regimens and consideration of the cost of care to hypertensive patients.
 Accupril -- as one agent, once a day, at one price -- supports JNC IV recommendations, which can be illustrated in the following excerpts from the report:
 -- "The goal of therapy is to control blood pressure with the fewest drugs at their lowest dose";
 -- Physicians should attempt "to decrease the dosage or number of antihypertensive drugs" patients must take;
 -- The treatment of hypertension should "take into consideration the lifestyles and concomitant conditions of individual patients" and "improve hypertension control while minimizing adverse effects";
 -- "Health-care providers should be aware of the total cost of care to hypertensive patients" and "try to minimize these expenses."
 The Accupril Single Agent Commitment Program
 As noted earlier, the Single Agent Commitment program provides a value-added service that reinforces the patient benefits of single-agent therapy. The program is simple for physicians and patients to use:
 -- The physician receives Single Agent Commitment packets, each containing five Diuretic Refund Certificates, through Parke-Davis representatives and direct mail.
 -- If, after an adequate trial of Accupril, the prescribing physician decides it is necessary to add a diuretic to the patient's Accupril regimen, the physician fills out the "physician" portion of the refund certificates and gives it to the patient.
 -- The patient completes the "patient" portion of the certificate, attaches proof of purchase for both Accupril and the diuretic, and mails all materials to the address on the certificate.
 -- Parke-Davis mails the refund check (less any amount reimbursed or paid for by an HMO, insurance company or any other plan or program) to the patient with additional Diuretic Refund Certificates.
 -- The program provides a toll-free telephone number (1-800-955-3077) to handle questions and additional orders.
 Parke-Davis is a leader in the treatment of cardiovascular disease. Among its cardiovascular products are the cholesterol-regulator Lopid(R) (gemfibrizel), the antianginal Nitrostat(R) (nitroglycerine), and the antiarrhythmic Procan(R) SR (procainamide hydrochloride).
 To further strengthen its cardiovascular position, Parke-Davis recently entered into an alliance with Boots Pharmaceuticals Inc. The two companies would co-market Boots' Manoplax(R) (flosequinan), a congestive heart failure drug now under FDA review, and Parke-Davis' Lopid. Lopid has achieved worldwide acceptance in the treatment of heart disease.
 Warner-Lambert is a worldwide company devoted to developing, manufacturing and marketing quality health-care and consumer products.
 -0- 12/10/91
 /CONTACT: Peter Wolf of Warner-Lambert, 201-540-6696; or Karen Pugliese of Creamer Dickson Basford, 212-887-8049, for Warner-Lambert/
 (WLA) CO: Parke-Davis; Warner-Lambert Company ST: New Jersey IN: MTC SU: PDT


JT -- NY025 -- 0980 12/10/91 11:31 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 10, 1991
Words:984
Previous Article:AMOCO STATIONS OFFER SPECIAL HOLIDAY PROMOTION IN CONJUNCTION WITH CHILDREN'S MIRACLE NETWORK
Next Article:HOECHST CELANESE DEVELOPING MAJOR PLASTICS RECYCLING COMPLEX AT ITS SPARTANBURG, S.C., PLANT
Topics:


Related Articles
WARNER-LAMBERT'S ACE INHIBITOR ACCUPRIL APPROVED FOR U.S. MARKETING FOR TREATMENT OF HYPERTENSION
PARKE-DAVIS LAUNCHES NICOTROL, FIRST NICOTINE PATCH FOR WAKING HOURS USE
UNIVERSITY OF MICHIGAN RECEIVES $5.5 MILLION FROM WARNER-LAMBERT FOR RESEARCH
FDA ADVISORY COMMITTEE REACHES UNANIMOUS APPROVAL RECOMMENDATION OF NEURONTIN FOR EPILEPSY
WARNER-LAMBERT, BASF ANNOUNCE LAB-TO-MARKET PHARMACEUTICAL COLLABORATION FOR ICE INHIBITORS
North American Launch of New Cholesterol-Lowering Drug Continues With Clearance in Canada
Unigene and Warner-Lambert Execute Letter of Intent to Develop Oral Calcitonin for Osteoporosis
GenVec Announces Collaboration with Parke-Davis; Focus on the BioByPass(TM) Product For The Treatment of Cardiovascular Diseases
Parke-Davis Signs Multi-Year Agreement with Tripos for Expanded Access to Discovery Software

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters